Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Operating Leases (2020 - 2025)

Immucell's Operating Leases history spans 6 years, with the latest figure at $4.0 million for Q4 2025.

  • For Q4 2025, Operating Leases fell 2.89% year-over-year to $4.0 million; the TTM value through Dec 2025 reached $4.0 million, down 2.89%, while the annual FY2025 figure was $4.0 million, 2.89% down from the prior year.
  • Operating Leases reached $4.0 million in Q4 2025 per ICCC's latest filing, down from $4.0 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $4.7 million in Q1 2024 to a low of $998114.0 in Q1 2022.
  • Average Operating Leases over 5 years is $3.0 million, with a median of $4.0 million recorded in 2025.
  • Peak YoY movement for Operating Leases: dropped 17.55% in 2022, then soared 299.21% in 2023.
  • A 5-year view of Operating Leases shows it stood at $1.0 million in 2021, then soared by 118.97% to $2.2 million in 2022, then surged by 81.27% to $4.1 million in 2023, then increased by 1.28% to $4.1 million in 2024, then fell by 2.89% to $4.0 million in 2025.
  • Per Business Quant, the three most recent readings for ICCC's Operating Leases are $4.0 million (Q4 2025), $4.0 million (Q3 2025), and $4.1 million (Q2 2025).